Keyword Analysis & Research: daiichi sankyo pipeline
Keyword Research: People who searched daiichi sankyo pipeline also searched
Search Results related to daiichi sankyo pipeline on Search Engine
-
Our Pipeline - Research & Development - Daiichi Sankyo
https://www.daiichisankyo.com/rd/pipeline/index.html
WebJan 31, 2024 · Our Pipeline. We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.
DA: 65 PA: 67 MOZ Rank: 41
-
Drug Development Pipeline - Daiichi Sankyo US
https://daiichisankyo.us/en/pipeline
WebOur Pipeline. Pipeline. An Ever-Expanding Portfolio of Promising New Compounds. Daiichi Sankyo is dedicated to the innovative development and commercialization of pharmaceutical products that address diversified, unmet medical needs in mature and emerging markets.
DA: 54 PA: 58 MOZ Rank: 85
-
Major R&D Pipeline
https://www.daiichisankyo.com/files/rd/pipeline/index/pdf/pipeline_2307_e.pdf
WebMajor R&D Pipeline: 5DXd-ADCs. As of Jul 2023 (US/EU/Asia) HER2+ BC 2L+/1L DESTINY-Breast07 (JP/US) solid tumors TROPION-PanTumor01 (US/EU/Asia) TNBC …
DA: 81 PA: 46 MOZ Rank: 62
-
Major R&D Pipeline: 3ADCs - Daiichi Sankyo
https://www.daiichisankyo.com/files/rd/pipeline/index/pdf/FY2022_3Q_Pipeline_ENG.pdf
WebAs of Jan 2023. Phase 1. (US/EU/Asia) HER2+ BC 2L+/1L DESTINY-Breast07. (US/EU/Asia) HER2 low BC Chemo naïve/ post chemo DESTINY-Breast08. (JP/US) NSCLC, TNBC, BC* 1, SCLC, GC, urothelial, esophageal, prostate, etc. TROPION-PanTumor01. (CN) NSCLC, TNBC. TROPION-PanTumor02. (US/EU/Asia) TNBC …
DA: 97 PA: 49 MOZ Rank: 60
-
Major R&D Pipeline: 3ADCs - Daiichi Sankyo
https://www.daiichisankyo.com/files/rd/pipeline/index/pdf/2022Q2pipeline_EN.pdf
WebMajor R&D Pipeline: Alpha. As of Oct 2022. Ifinatamab deruxtecan (I-Dxd, DS-7300) (JP/US) B7-H3-directed ADC ESCC, CRPC, squamous NSCLC, etc. PLX2853 (US) BET inhibitor AML Valemetostat (DS-3201)(JP/US/EU/Asia) EZH1/2 inhibitor PTCL Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor Quizartinib (JP/US/EU) …
DA: 87 PA: 70 MOZ Rank: 65
-
Pipeline | Daiichi Sankyo
https://www.daiichi-sankyo.eu/research-development/pipeline/
WebMar 7, 2023 · Pipeline. Our Focus. Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
DA: 87 PA: 31 MOZ Rank: 34
-
Press Releases - Daiichi Sankyo US
https://daiichisankyo.us/press-releases/-/article/patritumab-deruxtecan-granted-u-s-fda-breakthrough-therapy-designation-in-patients-with-metastatic-egfr-mutated-non-small-cell-lung-cancer
WebDec 23, 2021 · Tokyo, Munich and Basking Ridge, NJ – (December 23, 2021) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to patritumab deruxtecan (HER3-DXd), a potential first-in-class HER3 directed antibody …
DA: 79 PA: 27 MOZ Rank: 75
-
Major R&D Pipeline: 3ADCs - Daiichi Sankyo
https://www.daiichisankyo.com/files/rd/pipeline/index/pdf/FY2022Q1_Pipeline_E.pdf
WebMajor R&D Pipeline: Alpha. As of Jul 2022. Filed. Valemetostat (DS-3201) (JP) EZH1/2 inhibitor ATL/L. VN-0107/MEDI3250 (JP) Live attenuated influenza vaccine nasal spray. Oncology. Specialty medicine. Vaccin. e. project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
DA: 62 PA: 70 MOZ Rank: 76
-
Major R&D Pipeline: 3ADCs - Daiichi Sankyo
https://www.daiichisankyo.com/files/rd/pipeline/index/pdf/Pipeline_20210427_EN.pdf
WebApr 27, 2021 · EZH1/2 inhibitor PTCL. Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor. Lixiana (JP) FXa inhibitor AF in the very elderly. DS-6000 (US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer. PLX2853 (US) BET inhibitor AML. DS-1001 (JP) Mutant IDH1 inhibitor Glioma.
DA: 34 PA: 22 MOZ Rank: 69
-
Major R&D Pipeline: 3ADC - Daiichi Sankyo
https://www.daiichisankyo.com/files/rd/pipeline/index/pdf/FY2021_Q4%20(full%20year)_Pipeline_E3.pdf
WebDAIICHI SANKYO CO., LTD. Major R&D Pipeline: 3ADCs. As of Apr 2022. (Phase 1. Phase 2. Phase 3. Filed. BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer project in oncology that is planned to be submitted for approval based on.
DA: 6 PA: 1 MOZ Rank: 1
